Jump to Main Content
Growth arrest-specific gene 6 transfer promotes mesenchymal stem cell survival and cardiac repair under hypoxia and ischemia via enhanced autocrine signaling and paracrine action
- Shan, Shengshuai, Liu, Zhenyu, Guo, Tangmeng, Wang, Min, Tian, Shaobo, Zhang, Yanqing, Wang, Kun, Zheng, Huabo, Zhao, Xiaofang, Zuo, Peiyuan, Wang, Yingxuan, Li, Dazhu, Liu, Chengyun
- Archives of biochemistry and biophysics 2018 v.660 pp. 108-120
- adhesion, animal models, animals, apoptosis, autocrine signaling, cardiac output, cardiomyocytes, cell growth, cell viability, chemotaxis, coculture, gamma-carboxyglutamic acid, genes, heart failure, hypoxia, hypoxia-inducible factor 1, infarction, insulin-like growth factor I, mesenchymal stromal cells, mitogenesis, myocardial infarction, phosphatidylinositol 3-kinase, secretion, therapeutics, vascular endothelial growth factors
- Poor cell viability after transplantation has restricted the therapeutic capacity of mesenchymal stem cells (MSCs) for cardiac dysfunction after myocardial infarction (MI). Growth arrest-specific gene 6 (Gas6) encodes a secreted γ-carboxyglutamic acid (Gla)-containing protein that functions in cell growth, adhesion, chemotaxis, mitogenesis and cell survival. In this study, we genetically modified MSCs with Gas6 and evaluated cell survival, cardiac function, and infarct size in a rat model of MI via intramyocardial delivery. Functional studies demonstrated that Gas6 transfer significantly reduced MSC apoptosis, increased survival of MSCs in vitro and in vivo, and that Gas6-engineered MSCs (MSCGas6)-treated animals had smaller infarct size and showed remarkably functional recovery as compared with control MSCs (MSCNull)-treated animals. Mechanistically, Gas6 could enhance phosphatidylinositol 3-kinase (PI3K)/Akt signaling and improve hypoxia-inducible factor-1 alpha (HIF-1α)-driven secretion of four major growth factors (VEGF, bFGF, SDF and IGF-1) in MSCs under hypoxia in an Axl-dependent autocrine manner. The paracrine action of MSCGas6 was further validated by coculture neonatal rat cardiomyocytes with conditioned medium from hypoxia-treated MSCGas6, as well as by pretreatment cardiomyocytes with the specific receptor inhibitors of VEGF, bFGF, SDF and IGF-1. Collectively, our data suggest that Gas6 may advance the efficacy of MSC therapy for post-infarcted heart failure via enhanced Gas6/Axl autocrine prosurvival signaling and paracrine cytoprotective action.